Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA Sequencing of 16D Prostate Cancer Cell Lines with genetic knockout of OGDHL

ABSTRACT: RNA Sequencing of 16D Prostate Cancer Cell Lines with genetic knockout of OGDHL

PROVIDER: PRJNA1268387 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR33727281_1.fastq.gz	Fastqsanger.gz
	SRR33727281_2.fastq.gz	Fastqsanger.gz
	SRR33727282_1.fastq.gz	Fastqsanger.gz
	SRR33727282_2.fastq.gz	Fastqsanger.gz
	SRR33727283_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

RNA Sequencing of 16D prostate xenograft tumors with genetic knockout of OGDHL

Project description:RNA Sequencing of 16D prostate xenograft tumors with genetic knockout of OGDHL

| PRJNA1265110 | ENA

RNA Sequencing of 16D Prostate Cancer Cell Lines with genetic knockout of OGDHL

Project description:The goal of this study was to perform transcriptomics of prostate cancer cells with genetic knockout of OGDHL treated with the Androgen Receptor Pathway Inhibitor Enzalutamide (Enza) or Vehicle (DMSO)

2025-06-06 | GSE298123 | GEO

RNA Sequencing of 16D prostate xenograft tumors with genetic knockout of OGDHL

Project description:The goal of this study was to perform transcriptomics of xenograft tumors generated from prostate cancer cells with genetic knockout of OGDHL vs a control knockout

2025-06-06 | GSE297510 | GEO

RNA sequencing of 16D LTenza cells transduced with cMyc, shRb1, shTp53, shRb1_shTp53

Project description:The goal of this study was to determine how genetic alterations to AR inhibition-maintained prostate cancer cells alters transcriptional programs. We explored how MYC overexpression alters the transcriptional program of 16D cells maintained in enzalutamide for at least 2 months (LTenza) by transducing LTenza 16D cells with control (FUCRW) or MYC. To explore the effect of RB1 and TP53, we generated LTenza 16D cells with knockdown of RB1 and/or TP53 and compared these lines to control-transduced (shScr) LTenza 16D cells. Enzalutamide-naïve (DMSO-treated) cells were included to validate enzalutamide-induced inhibition of AR signaling in enzalutamide-maintained lines.

2022-05-12 | GSE202897 | GEO

RNA sequencing of 16D CRPC cells treated with enzalutamide over varying periods of time

Project description:The goal of this study was to determine how androgen receptor inhibition alters transcriptional programs in castration-resistant prostate cancer cells. 16D castration-resistant prostate cancer cells were grown in the presence of 10 micromolar enzalutamide for 24, 48, 96, 144 hours or for more than 2 months (long-term). Analysis shows that androgen receptor target genes are reduced with enzalutamide while metabolic genes are also differentially expressed.

2022-05-12 | GSE202885 | GEO

Proteomics of prostate cancer cell lines

Project description:We profiled the proteomics of prostate cancer (PCa) cell lines.

2024-12-06 | PXD058635 |

human prostate cell lines

Project description:human prostate cell lines

| PRJNA622489 | ENA

Men at High Genetic Risk for Prostate Cancer

Project description:Background: Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer. Objectives: To study men with specific genetic changes and determine who is at higher risk for getting prostate cancer. To study if certain genetic changes and family history can be used to help prevent or treat prostate cancer. Eligibility: Persons assigned male at birth ages 30-75 who have one or more specific genetic changes but without prostate cancer. Design: * This study does not perform genetic testing. All participants must have documented genetic changes and able to provide a copy of the report. * Before enrollment, participants will provide a copy of documented genetic changes and go through a telephone interview to determine eligibility for the study. * On enrollment, participants will have medical and family history review, medication review, physical exam, blood collection for clinical and research testing, and MRI (magnetic resonance imaging) of the prostate. * Every year, participants will repeat the physical exam, medical history, family history, medication review, routine blood tests, including PSA and testosterone. * Every 2 years, participants will repeat all the above plus prostate MRI and blood tests for research. * If, at any time, the physical exam, blood tests or MRI are abnormal, participants may be asked to do a biopsy. * If the biopsy results in prostate cancer, participants will be given counseling on next steps, general treatment recommendations, and then followed with a phone call each year. * Participants may ask to speak with a genetic counselor.

| 2294496 | ecrin-mdr-crc

Prostate Cancer Genetic Risk Evaluation and Screening Study

Project description:This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations or a positive family history and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.

| 2396203 | ecrin-mdr-crc

Schoenoplectus americanus strain:14-16D | cultivar:14-16D

Project description:Schoenoplectus americanus 14-16D Standard Draft genome sequencing

| PRJNA581021 | ENA